131 related articles for article (PubMed ID: 6414691)
21. Ifosfamide, mesna and vincristine in paediatric oncology.
de Kraker J; Voûte PA
Cancer Treat Rev; 1983 Sep; 10 Suppl A():165-6. PubMed ID: 6414690
[No Abstract] [Full Text] [Related]
22. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Cancer; 1984 Sep; 54(6 Suppl):1193-203. PubMed ID: 6432305
[TBL] [Abstract][Full Text] [Related]
23. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cantwell BM; Carmichael J; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
[TBL] [Abstract][Full Text] [Related]
25. Nursing implications in the administration of ifosfamide and mesna.
Richters JE
Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
[No Abstract] [Full Text] [Related]
26. Severe renal failure following high-dose ifosfamide and mesna.
Willemse PH; de Jong PE; Elema JD; Mulder NH
Cancer Chemother Pharmacol; 1989; 23(5):329-30. PubMed ID: 2495864
[TBL] [Abstract][Full Text] [Related]
27. Encephalopathy with rapid infusion ifosfamide/mesna.
Perren TJ; Turner RC; Smith IE
Lancet; 1987 Feb; 1(8529):390-1. PubMed ID: 2880199
[No Abstract] [Full Text] [Related]
28. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide/mesna nomogram and serum albumin.
Hill PG; Harrop JS
Lancet; 1986 Oct; 2(8513):986. PubMed ID: 2877171
[No Abstract] [Full Text] [Related]
30. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
31. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
32. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
Husband DJ; Watkin SW
Lancet; 1988 May; 1(8594):1116. PubMed ID: 2896952
[No Abstract] [Full Text] [Related]
33. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
[TBL] [Abstract][Full Text] [Related]
34. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
Sangster G; Kaye SB; Calman KC; Dalton JF
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
[No Abstract] [Full Text] [Related]
35. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
[TBL] [Abstract][Full Text] [Related]
38. Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.
Dorr RT
Semin Oncol; 1990 Aug; 17(4 Suppl 7):2-5. PubMed ID: 2116668
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
40. Ifosfamide, mesna, and encephalopathy.
Lancet; 1985 Jun; 1(8442):1398-9. PubMed ID: 2861351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
